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In this special issue of the Netherlands Heart Journal dif-
ferent aspects of pulmonary hypertension are elucidated.
Pulmonary hypertension (PH) is a haemodynamic state
defined as a mean pulmonary artery pressure of ≥25 mmHg
assessed by right heart catheterisation at rest [1]. Further-
more, PH can be divided into two main haemodynamic
profiles: a pre-capillary (with a pulmonary artery wedge
pressure (PAWP) ≤15 mmHg) and post-capillary form (with
a PAWP >15 mmHg).
Subsequently, PH can be found in different clinical con-
ditions and is categorised into five groups based on a sim-
ilar presentation, haemodynamic profile, pathological find-
ings, and treatment: pulmonary arterial hypertension (PAH)
(group 1), PH based on left heart disease (group 2), PH
due to lung disease and/or hypoxaemia (group 3), chronic
thromboembolic PH (CTEPH) (group 4), and PH with un-
clear and/or multifactorial mechanisms (group 5) [1, 2].
Patients with congenital heart disease (CHD) with a preva-
lent or corrected systemic-to-pulmonary shunt are at risk
for the development of PAH [3]. One of the best examples
of a disease associated with PH based on a multifactorial
aetiology (group 5) is sarcoidosis, a rare multisystemic dis-
order characterised by non-caseating granulomas that can
present in multiple tissues. Both pre- and post-capillary
forms of PH might be found. In a review by Huitema et al.
different aspects of PH in pulmonary sarcoidosis are de-
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scribed, underlying the importance of a multidisciplinary
approach [4].
The prevalence of PH varies between each group; left-
sided heart disease is the most common cause of PH. Up to
70 % of patients with severe chronic heart failure suffered
from PH [5], whereas the prevalence of pulmonary arte-
rial hypertension (PAH) is estimated to be between 15 and
60 patients per million population [6]. The estimated preva-
lence of PAH in CHD is about 10 %, depending on the
underlying defect and other characteristics [7]. In all sub-
groups of PH, quality of life (QoL) is decreased and mor-
tality substantially increased compared with patients with-
out PH. The most important predictors for survival are:
functional class or exercise capacity, QoL, performance of
the right ventricle and different pulmonary haemodynamic
measurements found by right heart catheterisation [1]. The
diagnosis of PAH has a tremendous psychosocial impact
on patients and their families, and is associated with a high
prevalence of anxiety and depression, in up to 40 % with
an impairment of QoL [8, 9].
Wapenaar et al. describe the validation of the disease-
specific Cambridge Pulmonary Hypertension Outcome Re-
view (CAMPHOR) for the Dutch population [10]. Dif-
ferent standard generic questionnaires for heart and lung
diseases have been used to report QoL in PH. However, the
CAMPHOR seems to be superior to the standard ques-
tionnaires in the assessment of PH-related outcome [11].
Therefore, it is important to use the Dutch version of this
questionnaire to have a valid and reliable measure of the
QoL in patients with PH.
Transthoracic echocardiography is mandatory as first-
line screening tool in patients at risk for the development
of PH or if the presence of PH is clinically suspected. Based
on the peak tricuspid regurgitation velocity (TRV) and the
presence of additional findings (including measurements of
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the right and left ventricle, pulmonary artery and inferior
vena cava or right atrium), the echocardiographic probabil-
ity of PH is divided into low (TRV <2.8 m/s without addi-
tional findings), intermediate or high (TRV 2.9 to 3.4 m/s
with additional findings or >3.4 m/s) [1]. Furthermore,
echocardiography can be helpful in detecting the cause of
PH, mainly associated with left and/or congenital heart dis-
ease and seems to predict outcome.
In a review article by Baggen et al., the association be-
tween different echocardiographic parameters and outcome,
defined as mortality or lung transplantation, was investi-
gated in a meta-analysis [12]. They found that the presence
of pericardial fluid, right atrial enlargement, and a decrease
in the tricuspid annular plane systolic excursion are the best
predictors for worse outcome.
Based on the echocardiographic probability of PH fur-
ther diagnostic evaluation should be performed to identify
the aetiology of PH, including pulmonary function tests,
chest CT and ventilation/perfusion scintigraphy to exclude
lung disease and pulmonary embolism [1, 13]. If PAH or
CTEPH is suspected the patient should be referred to an ex-
pert centre to confirm the diagnosis by specific diagnostic
tests, including right heart catheterisation. Goal-oriented
targeted PH-specific therapy is indicated in symptomatic
patients (functional class ≥2) with pulmonary vascular dis-
ease, besides general and supportive therapy [1]. The re-
sponse to this specific medication should be evaluated every
3 to 6 months based on symptoms, functional class, exer-
cise capacity, biomarkers, imaging and sometimes haemo-
dynamics.
Van Riel et al. evaluate the differences in clinical pre-
sentation and outcome after the initiation of PH-specific
therapy in patients with CHD in the Netherlands versus
Singapore [14]. They and others found that the time of
clinical presentation, effect and type of initial treatment
is influenced by differences in socioeconomic status and
healthcare systems [14, 15].
If the clinical response is inadequate sequential double or
triple therapy should be given, and maybe other appropriate
therapies should be discussed in a multidisciplinary team.
Couperus et al. describe the tailored interventional treat-
ment of complex CHD patients suffering from PH with an
impaired pulmonary flow, and emphasised the importance
of a multidisciplinary approach [16]. Next to optimal med-
ical PAH-specific therapy, an invasive circulatory adjust-
ment might be necessary to decrease right ventricular over-
load. Pre-procedural invasive pulmonary haemodynamic
measurement (including pulmonary vascular resistance and
effective left-to-right shunt quantification) is highly impor-
tant to evaluate the feasibility of shunt intervention to pre-
vent acute right ventricular failure [17]. Thereafter, each
case should be discussed within a multidisciplinary team
to reach consensus regarding patient treatment. Therefore,
the current guidelines recommend that treatment and fol-
low-up of patients with PAH (and PAH-CHD) should be
performed in tertiary centres using a multidisciplinary ap-
proach [1, 17].
Several aspects of pulmonary hypertension are high-
lighted in this special issue. These reviews and original
articles can further improve our knowledge of PH and
might improve our multidisciplinary care in daily practice.
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